$EYPT
EyePoint Pharmaceuticals, Inc. Stock $eypt

$eypt Overview Financials Valuation SEC Filings Company Website

2015 Q1 Form 10-Q Financial Statement

#000119312515179302 Filed on May 08, 2015

Income Statement

Concept	2015 Q1	2014 Q1
Revenue	$328.0K	$1.992M
YoY Change	-83.53%	288.3%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.040M	$1.950M
YoY Change	4.62%	12.07%
% of Gross Profit
Research & Development	$3.339M	$2.269M
YoY Change	47.16%	42.97%
% of Gross Profit
Depreciation & Amortization	$210.0K	$220.0K
YoY Change	-4.55%	-12.0%
% of Gross Profit
Operating Expenses	$5.380M	$4.211M
YoY Change	27.76%	26.65%
Operating Profit	-$5.052M	-$2.219M
YoY Change	127.67%	-21.09%
Interest Expense	$10.00K	$0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net	$10.00K	$1.000K
YoY Change	900.0%	-66.67%
Pretax Income	-$5.042M	-$2.218M
YoY Change	127.32%	-21.04%
Income Tax	-$44.00K	-$31.00K
% Of Pretax Income
Net Earnings	-$4.998M	-$2.187M
YoY Change	128.53%	-21.73%
Net Earnings / Revenue	-1523.78%	-109.79%
Basic Earnings Per Share	-$0.17	-$0.08
Diluted Earnings Per Share	-$0.17	-$0.08
COMMON SHARES
Basic Shares Outstanding	29.41M shares	27.67M shares
Diluted Shares Outstanding	29.41M shares	27.67M shares

Balance Sheet

Concept	2015 Q1	2014 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$31.70M	$21.30M
YoY Change	48.83%	55.47%
Cash & Equivalents	$23.01M	$18.56M
Short-Term Investments	$8.700M	$2.700M
Other Short-Term Assets	$1.000M	$600.0K
YoY Change	66.67%	20.0%
Inventory
Prepaid Expenses
Receivables	$400.0K	$600.0K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$33.08M	$22.46M
YoY Change	47.26%	47.73%
LONG-TERM ASSETS
Property, Plant & Equipment	$280.0K	$292.0K
YoY Change	-4.11%	30.94%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$300.0K	$300.0K
YoY Change	0.0%	200.0%
Total Long-Term Assets	$2.625M	$3.559M
YoY Change	-26.24%	-9.09%
TOTAL ASSETS
Total Short-Term Assets	$33.08M	$22.46M
Total Long-Term Assets	$2.625M	$3.559M
Total Assets	$35.70M	$26.02M
YoY Change	37.2%	36.09%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$812.0K	$761.0K
YoY Change	6.7%	114.37%
Accrued Expenses	$1.371M	$1.203M
YoY Change	13.97%	-16.28%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.218M	$2.276M
YoY Change	-2.55%	-15.23%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$5.600M	$5.400M
YoY Change	3.7%	3.85%
Total Long-Term Liabilities	$5.600M	$5.400M
YoY Change	3.7%	3.85%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.218M	$2.276M
Total Long-Term Liabilities	$5.600M	$5.400M
Total Liabilities	$7.855M	$7.675M
YoY Change	2.35%	-2.59%
SHAREHOLDERS EQUITY
Retained Earnings	-$265.5M	-$273.0M
YoY Change	-2.76%	5.13%
Common Stock	$29.00K	$29.00K
YoY Change	0.0%	26.09%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$27.85M	$18.35M
YoY Change
Total Liabilities & Shareholders Equity	$35.70M	$26.02M
YoY Change	37.2%	36.09%

Cashflow Statement

Concept	2015 Q1	2014 Q1
OPERATING ACTIVITIES
Net Income	-$4.998M	-$2.187M
YoY Change	128.53%	-21.73%
Depreciation, Depletion And Amortization	$210.0K	$220.0K
YoY Change	-4.55%	-12.0%
Cash From Operating Activities	-$3.960M	-$1.860M
YoY Change	112.9%	-5.58%
INVESTING ACTIVITIES
Capital Expenditures	-$40.00K	-$60.00K
YoY Change	-33.33%	500.0%
Acquisitions
YoY Change
Other Investing Activities	-$2.740M	-$2.210M
YoY Change	23.98%	-481.03%
Cash From Investing Activities	-$2.780M	-$2.260M
YoY Change	23.01%	-503.57%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$7.000M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	7.460M
YoY Change	-100.0%
NET CHANGE
Cash From Operating Activities	-3.960M	-1.860M
Cash From Investing Activities	-2.780M	-2.260M
Cash From Financing Activities	0.000	7.460M
Net Change In Cash	-6.740M	3.340M
YoY Change	-301.8%	-336.88%
FREE CASH FLOW
Cash From Operating Activities	-$3.960M	-$1.860M
Capital Expenditures	-$40.00K	-$60.00K
Free Cash Flow	-$3.920M	-$1.800M
YoY Change	117.78%	-8.16%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013Q3	us-gaap	Share Price SharePrice	3.10
CY2015Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	29412365	shares
CY2014Q4	psdv	Milestone Payment Received Upon Fda Approval MilestonePaymentReceivedUponFdaApproval	25000000
CY2015Q1	us-gaap	Liabilities Current LiabilitiesCurrent	2218000
CY2015Q1	us-gaap	Common Stock Value CommonStockValue	29000
CY2015Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2015Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	899000
CY2015Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	812000
CY2015Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	292439000
CY2015Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-265520000
CY2015Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1371000
CY2015Q1	us-gaap	Stockholders Equity StockholdersEquity	27847000
CY2015Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	49000
CY2015Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	35702000
CY2014Q1	us-gaap	Share Price SharePrice	4.11
CY2014Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2014Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18555000
CY2014Q1	psdv	Warrants Weighted Average Exercise Price WarrantsWeightedAverageExercisePrice	3.67
CY2015Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	29412365	shares
CY2015Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	29412365	shares
CY2015Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	60000000	shares
CY2015Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2015Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2015Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	5584000
CY2015Q1	us-gaap	Preferred Stock Value PreferredStockValue
CY2015Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	286000
CY2015Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	35000
CY2015Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2015Q1	us-gaap	Liabilities Liabilities	7855000
CY2015Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	618000
CY2015Q1	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	53000
CY2015Q1	us-gaap	Deferred Revenue DeferredRevenue	5600000
CY2015Q1	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2015Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	23007000
CY2015Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	280000
CY2015Q1	us-gaap	Assets Fair Value Disclosure Recurring AssetsFairValueDisclosureRecurring	25856000
CY2015Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	989000
CY2015Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	150000
CY2015Q1	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	430000
CY2015Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2080000
CY2015Q1	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	17205000
CY2015Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	8651000
CY2015Q1	us-gaap	Other Assets OtherAssets	115000
CY2015Q1	us-gaap	Security Deposit SecurityDeposit	150000
CY2015Q1	us-gaap	Assets Assets	35702000
CY2015Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	2300000
CY2015Q1	us-gaap	Assets Current AssetsCurrent	33077000
CY2015Q1	psdv	Collaboration Agreement Ownership Percentage In Company CollaborationAgreementOwnershipPercentageInCompany	0.063	pure
CY2015Q1	psdv	Warrants Weighted Average Exercise Price WarrantsWeightedAverageExercisePrice	3.67
CY2015Q1	psdv	Estimated Annual Amortization Of Intangible Assets EstimatedAnnualAmortizationOfIntangibleAssets	756000
CY2015Q1	psdv	Cash And Cash Equivalents And Marketable Securities Fair Value CashAndCashEquivalentsAndMarketableSecuritiesFairValue	31700000
CY2015Q1	psdv	Accrued Clinical Expense Current AccruedClinicalExpenseCurrent	418000
CY2013Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6899000
CY2014Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	29298558	shares
CY2014Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	29298558	shares
CY2014Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	60000000	shares
CY2014Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2014Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	5584000
CY2014Q2	us-gaap	Preferred Stock Value PreferredStockValue
CY2014Q2	us-gaap	Liabilities Current LiabilitiesCurrent	2126000
CY2014Q2	us-gaap	Common Stock Value CommonStockValue	29000
CY2014Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2014Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1044000
CY2014Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	464000
CY2014Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-277013000
CY2014Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1524000
CY2014Q2	us-gaap	Stockholders Equity StockholdersEquity	14924000
CY2014Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	7000
CY2014Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	22671000
CY2014Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	290864000
CY2014Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	249000
CY2014Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	138000
CY2014Q2	us-gaap	Liabilities Liabilities	7747000
CY2014Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	952000
CY2014Q2	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	37000
CY2014Q2	us-gaap	Deferred Revenue DeferredRevenue	5600000
CY2014Q2	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15334000
CY2014Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	297000
CY2014Q2	us-gaap	Assets Fair Value Disclosure Recurring AssetsFairValueDisclosureRecurring	17204000
	us-gaap	Increase Decrease In Accounts Receivable And Other Operating Assets IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets	-1016000
CY2014Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	547000
CY2014Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	150000
CY2014Q2	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	517000
CY2014Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2765000
CY2014Q2	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1000
CY2014Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	14260000
CY2014Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	2944000
CY2014Q2	us-gaap	Other Assets OtherAssets	117000
CY2014Q2	us-gaap	Assets Assets	22671000
CY2014Q2	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	2945000
CY2014Q2	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	2944000
CY2014Q2	us-gaap	Assets Current AssetsCurrent	19342000
CY2014Q2	psdv	Accrued Clinical Expense Current AccruedClinicalExpenseCurrent	316000
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.35
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-7886000
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	26841623	shares
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.35
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5069844	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	26841623	shares
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	100000
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	150000
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	99000
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-1000
	us-gaap	License And Services Revenue LicenseAndServicesRevenue	2149000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9475000
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	76000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-9478000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9289000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3000
	us-gaap	Royalty Revenue RoyaltyRevenue	1032000
	us-gaap	Revenues Revenues	3181000
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	2714000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	75000
	us-gaap	Net Income Loss NetIncomeLoss	-9388000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	3000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	963000
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-3000
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-290000
	us-gaap	Operating Expenses OperatingExpenses	12659000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7267000
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	582000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	11656000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-87000
	us-gaap	Depreciation Depreciation	103000
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	19058000
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	76000
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	26000
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	487000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	909000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5468000
	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	-833000
	us-gaap	Share Based Compensation ShareBasedCompensation	963000
	psdv	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	11000
	psdv	Warrants To Purchase Common Shares Outstanding And Exercisable WarrantsToPurchaseCommonSharesOutstandingAndExercisable	1176105	shares
	psdv	Proceeds From Issuance Of Common Stock Net Of Share Issue Costs ProceedsFromIssuanceOfCommonStockNetOfShareIssueCosts	18149000
	psdv	Noncash Or Part Noncash Unpaid Property Plant Equipment And Other Assets NoncashOrPartNoncashUnpaidPropertyPlantEquipmentAndOtherAssets	141000
	psdv	Proceeds From Maturity Of Marketable Securities ProceedsFromMaturityOfMarketableSecurities	3350000
	psdv	Noncash Or Part Noncash Unpaid Stock Issuance Costs NoncashOrPartNoncashUnpaidStockIssuanceCosts	86000
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.38
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.79	pure
	dei	Document Type DocumentType	10-Q
	dei	Entity Registrant Name EntityRegistrantName	pSivida Corp.
	dei	Trading Symbol TradingSymbol	PSDV
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.33
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y9M18D
	us-gaap	Nature Of Operations NatureOfOperations	<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">  </p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left"><b>1.</b></td> <td valign="top" align="left"><b>Operations and Basis of Presentation</b></td> </tr> </table> <!-- xbrl,body --> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The accompanying condensed consolidated financial statements of pSivida Corp. and subsidiaries (the “Company”) as of March 31, 2015 and for the three and nine months ended March 31, 2015 and 2014 are unaudited. Certain information in the footnote disclosures of these financial statements has been condensed or omitted in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”). These financial statements should be read in conjunction with the Company’s audited consolidated financial statements and footnotes included in its Annual Report on Form 10-K for the fiscal year ended June 30, 2014. In the opinion of management, these statements have been prepared on the same basis as the audited consolidated financial statements as of and for the year ended June 30, 2014, and include all adjustments, consisting only of normal recurring adjustments, that are necessary for the fair presentation of the Company’s financial position, results of operations, comprehensive (loss) income and cash flows for the periods indicated. The preparation of financial statements in accordance with U.S. generally accepted accounting principles (“GAAP”) requires management to make assumptions and estimates that affect, among other things, (i) reported amounts of assets and liabilities; (ii) disclosure of contingent assets and liabilities at the date of the consolidated financial statements; and (iii) reported amounts of revenues and expenses during the reporting period. The results of operations for the three and nine months ended March 31, 2015 are not necessarily indicative of the results that may be expected for the entire fiscal year or any future period.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The Company is a leader in the development of sustained-release pharmaceutical products for treating eye diseases. Its approved products deliver drugs at a controlled and steady rate for months or years. The Company has developed three of the four approved sustained-release products for treating retinal diseases. The Company’s lead product candidate Medidur™ for posterior uveitis is in pivotal clinical trials. Marketing of its lead licensed product ILUVIEN® for diabetic macular edema (“DME”) commenced in the U.S. in the fiscal 2015 third quarter. The Company’s pre-clinical development program is focused on developing products for chronic retinal diseases utilizing our core technology platforms. The Company’s strategy includes developing products independently while continuing to leverage our technology platforms through collaborations and license agreements.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> Medidur, the Company’s lead development product, is an injectable, micro-insert designed to treat posterior uveitis, a blinding eye disease, on a sustained basis for 36 months. Medidur uses the same micro-insert used in ILUVIEN for DME (same design, same drug, same polymers, same release rate) and delivers a lower dose of the same drug as Retisert<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">®</sup>, the Company’s approved implant for posterior uveitis. The Company is developing Medidur independently.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> In recent meetings, the Company reached agreement with the U.S. Food and Drug Administration (“FDA”) on a regulatory path for Medidur that should allow a new drug application (“NDA”) to be filed in the first half of 2017. The FDA indicated that, pending clinical trial results, it would accept an NDA based on data from the ongoing Medidur Phase III trial (which has a 12-month primary endpoint), data from a second Phase III trial with a shorter six-month primary endpoint and data referenced from the already completed Phase III ILUVIEN trials. The ongoing Phase III trial for Medidur completed enrollment with 129 patients in the fiscal 2015 third quarter. The last 12-month follow-up visit is scheduled in March 2016, and the Company expects top-line data in the second calendar quarter of 2016. The Company has already initiated a second Phase III Medidur trial, which will recruit up to 150 patients in India. Both trials will follow participants for three years.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The Company had previously planned to file an NDA with data from only the first Phase III trial and data referenced from the ILUVIEN studies, subject to FDA confirmation. Because of the shorter six-month primary endpoint permitted for the second trial, the Company expects that the new regulatory path will allow it to file the Medidur NDA with only a several month delay from the time frame anticipated with one Phase III trial. The Company had budgeted for a second Phase III trial, pending FDA guidance, so the second trial does not affect the Company’s liquidity projections.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The Company plans to commercialize Medidur with a newly designed, proprietary inserter that uses a standard 27 gauge needle routinely used in intraocular injections. As a result of the new design, the Company will conduct a utilization study on the new inserter, with data to be submitted as part of the Medidur NDA. Data from this study is expected to be available before data from the other trials and should not delay the NDA submission.</p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">  </p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"> ILUVIEN, the Company’s most recently approved product, is an injectable, sustained-release micro-insert that provides treatment of DME for three years from a single administration. ILUVIEN is licensed to and sold by Alimera Sciences, Inc. (“Alimera”), and the Company is entitled to a share of the net profits (as defined) from Alimera’s sales of ILUVIEN on a country-by-country basis. ILUVIEN was launched in the U.S. in late February 2015 and is now widely available to physicians in the U.S. It is indicated for the treatment of DME in patients previously treated with a course of corticosteroids without a clinically significant rise in intraocular pressure.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> ILUVIEN was also launched in Portugal in January 2015, and has been commercially available in the United Kingdom and Germany since June 2013. ILUVIEN has marketing approvals in 17 EU countries for the treatment of chronic DME considered insufficiently responsive to available therapies.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> Distribution, regulatory and reimbursement matters for ILUVIEN for DME in Australia and New Zealand have been sublicensed. The Company is entitled to 20% of any royalties and 33% of all other payments received by our licensee, including any milestone payments.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The Company’s pre-clinical research is primarily focused on developing pharmaceutical products to provide targeted and systemic sustained delivery of drugs and large biologic molecules for treatment of various conditions, and to provide sustained delivery of therapeutic agents to treat wet and dry age-related macular degeneration, glaucoma and osteoarthritis.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The Company has a history of operating losses and has financed its operations primarily from the receipt of license fees, milestone payments, research and development funding and royalty income from its collaboration partners and from proceeds of sales of its equity securities. The Company believes that its cash, cash equivalents and marketable securities of $31.7 million at March 31, 2015 will enable the Company to maintain its current and planned operations (including its two Medidur trials) into calendar year 2017. This estimate excludes any potential net profits receipts from sales of ILUVIEN.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> New accounting pronouncements are issued periodically by the Financial Accounting Standards Board (“FASB”) and are adopted by the Company as of the specified effective dates. Unless otherwise disclosed below, the Company believes that recently issued and adopted pronouncements will not have a material impact on the Company’s financial position, results of operations and cash flows or do not apply to the Company’s operations.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> In May 2014, the FASB issued Accounting Standards Update No. 2014-09, <i>Revenue from Contracts with Customers</i> (Topic 606) (“ASU 2014-09”), which requires an entity to recognize revenue in an amount that reflects the consideration to which the entity expects to be entitled in exchange for the transfer of promised goods or services to customers. The standard will replace most existing revenue recognition guidance in U.S. GAAP. In April 2015, the FASB tentatively deferred the effective date of ASU 2014-09, while also tentatively permitting early adoption. If such deferral is ratified, ASU 2014-09 will become effective on July 1, 2018. The standard permits the use of either the retrospective or cumulative effect transition method. The Company is evaluating the impact this standard will have on its financial statements.</p> </div>
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	13303000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	579408	shares
	dei	Document Period End Date DocumentPeriodEndDate	2015-03-31
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0170	pure
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	30612210	shares
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.39
	dei	Entity Central Index Key EntityCentralIndexKey	0001314102
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.93	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0200	pure
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2434024	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29366919	shares
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-141000
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-145000
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-4000
	us-gaap	License And Services Revenue LicenseAndServicesRevenue	25355000
	us-gaap	Increase Decrease In Accounts Receivable And Other Operating Assets IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets	388000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	11637000
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	235000
	us-gaap	Operating Income Loss OperatingIncomeLoss	11621000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	11348000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	16000
	us-gaap	Income Taxes Paid IncomeTaxesPaid	263000
	us-gaap	Royalty Revenue RoyaltyRevenue	801000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4000
	us-gaap	Revenues Revenues	26156000
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	8677000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	71000
	us-gaap	Net Income Loss NetIncomeLoss	11493000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	12000
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1340000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1340000
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-17000
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-103000
	us-gaap	Operating Expenses OperatingExpenses	14535000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8890000
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	579000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	7673000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	144000
	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	263000
CY2014Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5069844	shares
CY2014Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	27672327	shares
	us-gaap	Depreciation Depreciation	79000
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	235000
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	66000
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-5848000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	235000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5645000
	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	221000
	us-gaap	Share Based Compensation ShareBasedCompensation	1340000
	psdv	Incremental Common Shares Attributable To Warrants IncrementalCommonSharesAttributableToWarrants	255301	shares
	psdv	Marketable Securities Weighted Average Maturity MarketableSecuritiesWeightedAverageMaturity	P7M3D
	psdv	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	16000
	psdv	Warrants To Purchase Common Shares Outstanding And Exercisable WarrantsToPurchaseCommonSharesOutstandingAndExercisable	1176105	shares
	psdv	Incremental Common Shares Attributable To Call Options IncrementalCommonSharesAttributableToCallOptions	989990	shares
	psdv	Warrants Outstanding Weighted Average Remaining Contract Life WarrantsOutstandingWeightedAverageRemainingContractLife	P1Y7M6D
	psdv	Proceeds From Maturity Of Marketable Securities ProceedsFromMaturityOfMarketableSecurities	2900000
CY2013Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	3494550	shares
CY2013Q3	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	890000
CY2013Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	10800000
CY2014Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	1700000	shares
CY2014Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	191000
CY2014Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	7000000
CY2014Q1	psdv	Number Of Institutional Investors NumberOfInstitutionalInvestors	1	Investor
CY2014Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.08
CY2014Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	27672327	shares
CY2014Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.08
CY2014Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	5000
CY2014Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	4000
CY2014Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-1000
CY2014Q1	us-gaap	License And Services Revenue LicenseAndServicesRevenue	1676000
CY2014Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2218000
CY2014Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	4000
CY2014Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2219000
CY2014Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2183000
CY2014Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1000
CY2014Q1	us-gaap	Royalty Revenue RoyaltyRevenue	316000
CY2014Q1	us-gaap	Revenues Revenues	1992000
CY2014Q1	us-gaap	Net Income Loss NetIncomeLoss	-2187000
CY2014Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	1000
CY2014Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	441000
CY2014Q1	us-gaap	Operating Expenses OperatingExpenses	4211000
CY2014Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2269000
CY2015Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5042000
CY2015Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-5052000
CY2015Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5042000
CY2015Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	190000
CY2015Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	10000
CY2015Q1	us-gaap	Royalty Revenue RoyaltyRevenue	218000
CY2015Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4000
CY2015Q1	us-gaap	Revenues Revenues	328000
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	-4998000
CY2015Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	6000
CY2015Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	614000
CY2015Q1	us-gaap	Operating Expenses OperatingExpenses	5380000
CY2015Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3339000
CY2014Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	196000
CY2014Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-31000
CY2014Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1946000
CY2015Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.17
CY2015Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29412365	shares
CY2015Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.17
CY2015Q1	us-gaap	Finite Lived Intangible Assets Remaining Amortization Period1 FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1	P2Y9M
CY2015Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5667054	shares
CY2015Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29412365	shares
CY2015Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-45000
CY2015Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-44000
CY2015Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	1000
CY2015Q1	us-gaap	License And Services Revenue LicenseAndServicesRevenue	110000
CY2015Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-44000
CY2015Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2041000
CY2015Q1	psdv	Trial Participant Follow Up Period TrialParticipantFollowUpPeriod	P3Y

Files In Submission

Name	View Source	Status
0001193125-15-179302-index-headers.html	Edgar Link	pending
0001193125-15-179302-index.html	Edgar Link	pending
0001193125-15-179302.txt	Edgar Link	pending
0001193125-15-179302-xbrl.zip	Edgar Link	pending
d911428d10q.htm	Edgar Link	pending
d911428dex311.htm	Edgar Link	pending
d911428dex312.htm	Edgar Link	pending
d911428dex321.htm	Edgar Link	pending
d911428dex322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
psdv-20150331.xml	Edgar Link	completed
psdv-20150331.xsd	Edgar Link	pending
psdv-20150331_cal.xml	Edgar Link	unprocessable
psdv-20150331_def.xml	Edgar Link	unprocessable
psdv-20150331_lab.xml	Edgar Link	unprocessable
psdv-20150331_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EYPT
EyePoint Pharmaceuticals, Inc. Stock $eypt

2015 Q1 Form 10-Q Financial Statement

#000119312515179302 Filed on May 08, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EYPT EyePoint Pharmaceuticals, Inc. Stock $eypt

2015 Q1 Form 10-Q Financial Statement

#000119312515179302 Filed on May 08, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EYPT
EyePoint Pharmaceuticals, Inc. Stock $eypt